BioRestorative Therapies, Inc. (BRTX)
| Market Cap | 9.69M |
| Revenue (ttm) | 377,000 |
| Net Income (ttm) | -1.95M |
| Shares Out | 6.92M |
| EPS (ttm) | -0.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,664 |
| Open | 1.440 |
| Previous Close | 1.340 |
| Day's Range | 1.380 - 1.440 |
| 52-Week Range | 1.030 - 3.670 |
| Beta | 62.79 |
| Analysts | Strong Buy |
| Price Target | 18.00 (+1,185.71%) |
| Earnings Date | Nov 12, 2024 |
About BRTX
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a... [Read more]
Financial Performance
In 2023, BioRestorative Therapies's revenue was $145,800, an increase of 21.70% compared to the previous year's $119,800. Losses were -$10.42 million, -21.21% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for BRTX stock is "Strong Buy" and the 12-month stock price forecast is $18.0.
News
BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Lance Alstodt – Chairman and Chief ...
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
– Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research –
BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
MELVILLE, N.Y., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a regenerative medicine innovator focused on stem cell-ba...
BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs
MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage regenerative medicine innovator focused ...
BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:03 PM ET BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q2 2024 Earnings Conference Call August 13, 2024, 16:30 PM ET Company Participants Lance Alstodt - President,...
BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorat...
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
– Adds to comprehensive patent portfolio underlying novel ThermoStem ® technology platform –
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) -- BioRest...
BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders –
BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference
MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today...
BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice
MELVILLE, N.Y., May 24, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therap...
BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market
MELVILLE, NY / ACCESSWIRE / May 15, 2024 / As advancements in technology make it easier to enhance natural beauty, the global aesthetics market, which was worth $75.46 billion in 2023, is expected to ...
BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Stephen Kilmer - Head of Investor Relations Lance Alstodt - President, Chief...
BioRestorative Therapies Provides First Quarter 2024 Business Update
MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapi...
BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity
— New therapeutic candidate developed using Company's patented ThermoStem ® platform —
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity -
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology
— Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform —
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
— Collaboration follows recent manufacturing/clinical process enhancements that have tripled monthly trial capacity —
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
- Company is not offering shares pursuant to the registration statement - MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) ...
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based thera...
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, t...
BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting
MELVILLE, NY / ACCESSWIRE / February 14, 2024 / BioRestorative Therapies (NASDAQ:BRTX) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease ...
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
MELVILEE, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, toda...
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company to host webcasted conference call today at 8:30am EST — MELVILLE, N.Y., Feb. 05, 2024 (GLOB...